Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
cell imaging multimode readertechnical
A cell imaging multimode reader is a laboratory instrument that takes pictures and measurements of cells using several detection methods (for example, bright light, fluorescent tags, or light-emitting reactions), much like a camera with interchangeable lenses and filters. It matters to investors because these machines speed up and standardize experiments used in drug discovery, diagnostics and biotech research, driving sales of high-value instruments and recurring revenue from consumables and software tied to ongoing scientific programs.
multimode microplate readingtechnical
Multimode microplate reading is a laboratory instrument capability that measures chemical or biological reactions in many small wells using different ways of detecting signals, such as color changes, glow, or fluorescence. For investors, it signals flexibility and efficiency in research and testing—one machine replaces several single-purpose devices, speeding experiments and reducing costs while enabling a wider range of assays and faster data-driven decisions about product development or diagnostics.
high-content cell imagingmedical
A laboratory method that takes large numbers of detailed, labeled photographs of individual cells to track how they change under different conditions, like a time-lapse photo album for microscopic biology. Investors care because it helps companies test drugs and materials faster and with clearer visual evidence of effects, reducing development risk and providing measurable milestones that can influence valuations and partnership or approval prospects.
high‑content screeningmedical
An automated laboratory method that takes large numbers of detailed images of cells or tissues and uses computer analysis to measure many biological features at once, like size, shape, and activity. For investors, it matters because it helps scientists identify promising drug candidates faster and with more detail—reducing R&D risk, shortening timelines, and increasing the potential value of pipelines or partnerships by providing richer evidence of a compound’s effects.
cell-based assaysmedical
Cell-based assays are laboratory tests that use living cells to see how a drug, chemical or biological agent affects biological functions such as growth, signaling or toxicity. Think of them as a test kitchen where ingredients (candidate drugs) are tried on real recipes (cells) to see whether they produce the desired result or cause harm. For investors, these assays provide early evidence about a treatment’s likely effectiveness and safety, guiding R&D value, risk and development timelines.
biochemical assaysmedical
Biochemical assays are laboratory tests that measure the presence, amount or activity of specific molecules or biological reactions, like checking how well a drug binds to a target or whether a diagnostic detects a marker. Think of them as taste-tests in a kitchen that reveal whether a recipe is working; for investors, assay results indicate whether a candidate therapy or test is effective, reproducible and likely to clear regulatory reviews, which directly affects a biotech or diagnostics company’s prospects and valuation.
inverted fluorescence microscopymedical
A laboratory microscope designed with its lenses and light source beneath the stage so researchers can view cells and tissues grown in dishes or flasks without disturbing them; think of it as a camera that photographs people through a window instead of moving them. Investors should care because this tool is central to biological research, drug discovery and quality testing—its use signals active lab work, reliable cell-based data, and potential progress in development programs that can affect a company’s valuation.
microplate readertechnical
A microplate reader is a laboratory instrument that quickly measures signals—usually light absorption, fluorescence or luminescence—from many tiny samples arranged in a flat “plate,” like a scanner reading thousands of miniature test tubes at once. Investors care because these readers are essential for drug discovery, diagnostics and research workflows; their speed, accuracy and consumable needs drive recurring revenue and influence how fast companies can generate reliable data and bring products to market.
SANTA CLARA, Calif.--(BUSINESS WIRE)--
Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform.
Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic research through high‑content screening.
Designed for researchers running both cell-based and biochemical assays, Cytation 9 brings expanded imaging capabilities along with advanced hybrid microplate detection technologies. Key features include inverted fluorescence microscopy, upright imaging, and a multimode microplate reader module in a single instrument, helping laboratories streamline workflows while maintaining flexibility across diverse applications.
Since first introduced in 2013, the BioTek Cytation portfolio has served as an industry standard for combined multimode microplate reading and high-content cell imaging. With continued evolution of the product line, Cytation 9 is designed to support more rigorous research demands—including in pharmaceutical and biotechnology laboratories—where workflows require faster, higher-throughput capabilities and adaptable tools for advanced cell-based models used in disease and drug discovery research.
“For over a decade, Agilent’s Cytation imagers have been used to automate tedious manual microscopy work and complex image analysis tasks,” said Xavier Amouretti, Vice President, BioTek and Seahorse Business Unit Leader, at Agilent. “Cytation 9 is designed around the same principles, with a broader application range and twice the imaging speed. This comes from direct feedback from thousands of Cytation users. We believe Cytation 9 will help accelerate the next wave of discoveries in cell biology and drug development.”
About Agilent Technologies
Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
